Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of oatp1b1s

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 592-601

  Van De Steeg, E ^a   Greupink, R ^b   Schreurs, M ^b   Nooijen, I H G ^a   Verhoeck, K C M ^a   Hanemaaijer, R ^a   Ripken, D ^a   Monshouwer, M ^c   Vlaming, M L H ^a   DeGroot, J ^a   Verwei, M ^a   Russel, F G M ^b   Huisman, M T ^c   Wortelboer, H M ^a  

^a TNO   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Drug Metabolism and Pharmacokinetics   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL 17 GLUCURONIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; ORGANIC ANION TRANSPORTER 2; PIOGLITAZONE; RECOMBINANT PROTEIN; ROSUVASTATIN; TOLBUTAMIDE; TROGLITAZONE;

ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MICHAELIS CONSTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ESTRADIOL; FLUOROBENZENES; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; SULFONAMIDES; TANDEM MASS SPECTROMETRY; TRANSFECTION;

EID: 84874040358     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049023     Document Type: Article

References (40)

1. Akhlaghi F, McLachlan AJ, Keogh AM, and Brown KF (1997) Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 44:537-542.
2. Aquilante CL (2010) Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 8:359-372.
3. Asberg A (2003) Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63:367-378.
4. Bednarczyk D (2010) Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3. Anal Biochem 405:50-58.
5. Brunton LL, Chabner BA, and Knollmann BC. (2011) Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw Hill, Columbus
6. Cheng F, Yu Y, Zhou Y, Shen Z, Xiao W, Liu G, Li W, Lee PW, and Tang Y (2011) Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds. J Chem Inf Model 51:2482-2495.
7. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, and Park K (2008) Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 83: 251-257.
8. Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, and Song IS (2011) Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic aniontransporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41:24-34.
9. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, and Jang IJ (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342-350.
10. Fahrmayr C, Fromm MF, and König J (2010) Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 42: 380-401.
11. Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, and Holdaas H (2008) Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 23:1048-1053.
12. Gui C, Wahlgren B, Lushington GH, and Hagenbuch B (2009) Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. Pharmacol Res 60:50-56.
13. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: Phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665.
14. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
15. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
16. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, and Kivistö KT (2006) Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79:419-426.
17. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
18. Iwai M, Suzuki H, Ieiri I, Otsubo K, and Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749-757.
19. Kalliokoski A, Neuvonen PJ, and Niemi M (2010) SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 107:775-781.
20. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel insilico peptide selection criteria. Pharm Res 25:1469-1483.
21. Kindla J, Müller F, Mieth M, Fromm MF, and König J (2011) Influence of non-steroidal antiinflammatory drugs on organic anion transporting polypeptide (OATP) 1B1-and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047-1053.
22. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
23. König J, Seithel A, Gradhand U, and Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372:432-443.
24. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, and Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330-341.
25. Lewis DF, Lake BG, and Dickins M (2006) Quantitative structure-activity relationships (QSars) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding. J Enzyme Inhib Med Chem 21:127-132.
26. Martin PD, Warwick MJ, Dane AL, Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563.
27. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, and Blasetto JW; STELLAR Study Group (2003) Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 19:689-698.
28. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, and Zinman B; American Diabetes Association; ; European Association for Study of Diabetes (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203.
29. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581.
30. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, and Neuvonen PJ, et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440.
31. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, and Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77: 468-478.
32. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
33. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, and Tamai I (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 32: 291-294.
34. Pasanen MK, Fredrikson H, Neuvonen PJ, and Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733.
35. Pasanen MK, Neuvonen PJ, and Niemi M (2008) Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19-33.
36. Regev-Shoshani G, Shoseyov O, and Kerem Z (2004) Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biophys Res Commun 323 B. 668-673
37. Roth M, Araya JJ, Timmermann BN, and Hagenbuch B (2011) Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J Pharmacol Exp Ther 339:624-632.
38. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177.
39. Spencer CM and Markham A (1997) Troglitazone. Drugs 54:89-101, discussion 102.
40. Zheng HX, Huang Y, Frassetto LA, and Benet LZ (2009) Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78-85.